Quest Diagnostics Names Benjamin Beauvalot Senior Vice President, Chief Strategy and M&A Officer
Quest Diagnostics (NYSE: DGX) named Benjamin Beauvalot senior vice president, chief strategy and M&A officer, effective Feb. 26, 2026.
Rhea-AI Summary
Quest Diagnostics (NYSE: DGX) named Benjamin Beauvalot senior vice president, chief strategy and M&A officer, effective Feb. 26, 2026. He brings more than 20 years of strategy, M&A and transformation experience from Danaher, Patheon and Banner Life Sciences.
Mr. Beauvalot will lead growth strategy, mergers and acquisitions, strategic partnerships and integrations, reporting to Jim Davis and joining the executive leadership team. He succeeds Dermot Shorten, who will retire in Q2 2026 after overseeing nearly 80 business combinations, including about 20 hospital outreach lab acquisitions.
Positive
- New SVP has over 20 years of strategy and M&A experience
- Role covers growth strategy, M&A, partnerships, and integrations
- Reports directly to CEO and joins executive leadership team
- Company completed nearly 80 business combinations historically
- Approximately 20 hospital outreach laboratory acquisitions over past decade
Negative
- Departure of longtime M&A leader (Dermot Shorten) in Q2 2026
- Short-term transition risk from leadership change during integration activity
Details
News Market Reaction – DGX
In the Feb 26 session, DGX gained 1.59%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- M&A experience
- more than two decades
- Benjamin Beauvalot experience in business strategy and transformation
- Business combinations
- nearly 80
- Business combinations and collaborations overseen by Dermot Shorten at Quest
- Hospital lab acquisitions
- approximately 20
- Acquisitions of hospital outreach laboratories over the past decade
- Role tenure
- since 2008
- Dermot Shorten’s tenure as chief strategy and M&A leader
- Patheon acquisition year
- 2017
- Patheon acquired by Thermo Fisher Scientific
- Service duration
- 18 years
- Length of Dermot Shorten’s service at Quest Diagnostics
- Current price
- $207.80
- Close prior to management change announcement
- 52-week range
- $157.20–$213.20
- 52-week low and high before this news
Historical Context
-
CFO scheduled to speak at Leerink 2026 healthcare conference.
-
Strong Q4 and 2025 results, raised 2026 guidance and higher EPS outlook.
-
7.5% dividend increase and $1B boost to share repurchase authorization.
-
Launch of ultrasensitive flow cytometry MRD blood test for myeloma.
-
Named to Fortune’s 2026 Most Admired Companies list for 12th year.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
m&a financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Veteran M&A and transformation leader from Danaher and Patheon joins the Quest Diagnostics executive team
In this role, Mr. Beauvalot is responsible for developing the company's growth strategy and leading mergers and acquisitions, strategic partnerships, and integrations. He reports to Jim Davis, chairman, CEO and president, and is a member of the company's executive leadership team.
"Ben has an extensive track record of delivering successful growth, M&A and transformation strategies for world-class healthcare organizations," Mr. Davis said. "His strategic leadership and rigorous approach to business integration will advance Quest's opportunities to generate organic and acquisitive growth, thereby supporting our purpose to create a healthier world, one life at a time."
Prior to joining Quest, Mr. Beauvalot held leadership positions in strategy and M&A with Danaher Corporation, a leading global life sciences and diagnostics innovator. Mr. Beauvalot's roles included vice president and head of business development and strategy for Danaher's biotechnology and genomics business areas. Mr. Beauvalot also served as vice president of strategy and corporate development and vice president of global business operations for Patheon, a leading pharmaceutical services company, before its acquisition by Thermo Fisher Scientific in 2017. He was also vice president of strategy for Banner Life Sciences, a specialty pharmaceutical company.
Mr. Beauvalot holds a degree in management and business administration from the Institut de Préparation à l'Administration et à la Gestion (IPAG) in
Mr. Beauvalot succeeds Dermot Shorten, who is retiring in the second quarter of 2026 after having held the role since 2008. During his time at Quest, Mr. Shorten oversaw nearly 80 business combinations and collaborations, including approximately 20 acquisitions of hospital outreach laboratories over the past decade.
"On behalf of the entire executive team and all of my Quest colleagues, I am grateful to Dermot for his leadership and contributions, many of which were strategically critical to creating the strong, dynamic business Quest is today," Mr. Davis said. "He played a vital role stewarding our company's successes over the past 18 years and is leaving us with a solid foundation for creating further growth and value."
About Quest Diagnostics
Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take action to improve health outcomes. Derived from one of the world's largest databases of de-identifiable clinical lab results, Quest's diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in
View original content to download multimedia:https://www.prnewswire.com/news-releases/quest-diagnostics-names-benjamin-beauvalot-senior-vice-president-chief-strategy-and-ma-officer-302698430.html
SOURCE Quest Diagnostics
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.